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Background:  Elevated levels of Hepatocyte Growth Factor (HGF) have been observed in patients with systemic amyloidosis but little is known 
about HGF and other biomarkers in patients with cardiac amyloid. We hypothesized that HGF levels can discriminate patients with cardiac amyloid 
from those with left ventricular hypertrophy (LVH) and diastolic heart failure (DHF) who are morphologically indistinct on echocardiography (echo).
Methods:  Serum HGF was measured and echo features were assessed in 17 patients with cardiac amyloid, 17 patients with LVH on echo, and 
18 patients with diastolic heart failure enrolled in an outpatient registry. Cardiac amyloid was diagnosed by biopsy (9/17) or cardiac magnetic 
resonance imaging (8/17).
Results: Clinical, echo, and HGF data are presented in Table 1 (mean ± SD). There were no echocardiographic differences among the three groups 
in terms of LV size and function and LA size. HGF was significant elevated in patients with cardiac amyloid. 
Table 1. Clinical, Echocardiographic, and HFG Data
Measurement
Amyloid
(n = 17)
LVH 
(n = 17)
DHF
(n = 18)
p value
Age, years 61.3 ± 9.9 59.7 ± 13.9 64.4 ± 17.0 NS
Sex, % male 67 61 28
LV Ejection Fraction, % 52.0 ± 14.8 58.2 ± 9.6 60.2 ± 8.8 NS
Interventricular septum thickness, cm 1.5 ± 0.4 1.6 ± 0.6 1.7 ± 0.4 NS
End-diastolic dimension, cm 4.3 ± 0.4 4.5 ± 0.9 4.7 ± 0.9 NS
End-systolic dimension, cm 3.1 ± 0.5 3.0 ± 1.0 3.1 ± 1.1 NS
Left atrial dimension, cm 4.3 ± 0.6 4.5 ± 0.7 4.6 ± 1.0 NS
HGF, pg/mL 2097 ± 5424 165.1 ± 58.4 162.4 ± 65.0
< 0.001 for amyloid vs. LVH
< 0.001 for amyloid vs. DHF
= 0.7 for LVH vs. DHF
Conclusions:  HGF is markedly elevated in patients with cardiac amyloidosis and may help diagnose cardiac amyloidosis in patients with LVH and 
DHF who are echocardiographically indistinct. These findings suggest that measurement of HGF can be confirmatory for the diagnosis of cardiac 
amyloid and may minimize the need for invasive or extensive testing.
